WO2007116432A1 - キャノロールまたはそのプロドラッグ(pd)を含む抗炎症剤および癌予防剤ならびにこれらを含む医薬、化粧品および食品 - Google Patents
キャノロールまたはそのプロドラッグ(pd)を含む抗炎症剤および癌予防剤ならびにこれらを含む医薬、化粧品および食品 Download PDFInfo
- Publication number
- WO2007116432A1 WO2007116432A1 PCT/JP2006/306617 JP2006306617W WO2007116432A1 WO 2007116432 A1 WO2007116432 A1 WO 2007116432A1 JP 2006306617 W JP2006306617 W JP 2006306617W WO 2007116432 A1 WO2007116432 A1 WO 2007116432A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inflammatory
- cancer
- canolol
- inflammatory agent
- cancer preventive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an anti-inflammatory agent and a cancer preventive agent comprising canolol or a prodrug thereof (PD), and a medicament, cosmetic and food containing the same.
- Anti-inflammatory agents are substances that suppress the production of inflammatory site force-in and inflammatory mediators (prostaglandins and the like.
- As anti-inflammatory agents aspirin and teprenone are known.
- cancer preventive agents are substances that prevent carcinogenic substances from being ingested or carcinogenic due to chronic watching, and currently there are no known prominent ones.
- lipid peroxide radicals derived from lipid peroxides that are harmful to living bodies (eg, DNA cleavage and cytotoxicity).
- LEO ⁇ lipid peroxide radicals
- canolol exhibits a strong erasing activity against LOO ', which is harmful to living organisms.
- canolol has a neutralizing activity against LOO, it has been considered to be used as a pharmaceutical ingredient, cosmetic ingredient and food ingredient.
- canolol has a high therapeutic effect or preventive activity against inflammation and cancer.
- the invention has been completed. More specifically, the present inventors examined the preventive effect on the occurrence of gastric cancer by the system of chronic infection model in animals using gerbils infected with bacteria (hericopacter pylori, Helicobacter pylori). As a result of further research, the present invention was completed as a result of further research on the gastroduodenal inflammation caused by Helicobacter pylori. It was.
- the present invention provides (1) 4 Bull 2, 6 Dimethoxyphenol
- the present invention may include one or two from gastric / duodenal inflammation, stomach, duodenal ulcer, gastritis, bronchitis, rheumatism, hepatitis, colitis, conjunctivitis, pneumonia, splenitis, stomatitis, pharyngitis and burns.
- the anti-inflammatory agent for the treatment of species or more.
- the present invention provides the inhibition of 8-oxodeoxyguanosine production and the inhibition of COX-2 activity.
- the present invention relates to the above-mentioned anti-inflammatory agent, which suppresses inflammation by one or two of harm, NO synthase (iNOS) activity inhibition, and NO production inhibition.
- iNOS NO synthase
- the present invention also relates to the cancer preventive agent which prevents carcinogenesis by inhibiting mutagenicity with peroxynitrite.
- the present invention also relates to the anti-inflammatory agent or cancer preventive agent (medicine) further comprising a pharmaceutical excipient.
- the present invention also relates to the anti-inflammatory agent or cancer preventive agent (cosmetic) further comprising a cosmetic component (cosmetic component).
- the present invention relates to the anti-inflammatory agent or cancer preventive agent for treating one or more of skin aging, cell injury and sunburn power, comprising a cosmetic ingredient.
- the present invention also relates to the anti-inflammatory agent or cancer preventive agent (pharmaceutical product or cosmetic product) having the form of cream, tablet, capsule, oil preparation, water-soluble drug (water-solubilized product) or emulsion.
- this invention relates to the said anti-inflammatory agent or cancer preventive agent (foodstuff) which contains a foodstuff component further.
- the active ingredient used in the present invention is excellent in the following respects:
- Antioxidants extracted from conventional rapeseed defatted rice bran are sparingly soluble in water, but are extracted from rapeseed raw oil and easily dissolved in fats and oils. Easy to use as an oxidizing agent.
- the anti-inflammatory agent and cancer preventive agent of the present invention are conventional in terms of ease of production, production cost, biological activity, safety, and administration. Has an extraordinary effect.
- gastric 'duodenal inflammation gastric' duodenal ulcer, gastritis, tracheositis, rheumatism, hepatitis, colitis, conjunctivitis, pneumonia, knee inflammation, stomatitis, pharyngitis and burns
- gastric'duodenal inflammation gastric' duodenal ulcer, gastritis, tracheositis, rheumatism, hepatitis, colitis, conjunctivitis, pneumonia, knee inflammation, stomatitis, pharyngitis and burns
- the production of 8-oxodeoxyguanosine is suppressed, the activity of COX-2 is inhibited, the activity of iNOS is inhibited (suppression of NO production), and the induction of cytoforce in is also suppressed.
- Those that suppress inflammation by one or two species have the effect of being able to be used for the treatment of a wide variety of inflammations by having various mechanisms of action (reference: due to plant components such as flavonoids) Suppression of site force-in generation JK Kundu, YJ Surh, Mutation Res. 591, 123-146 (2005)).
- cancer preventive agents of the present invention agents that prevent carcinogenesis by inhibiting mutagenicity with peroxynitrite have an effect as cancer preventive agents.
- those further containing a pharmaceutical excipient have the effect of being able to easily treat diseases.
- those further containing a cosmetic ingredient are used as cosmetics and exhibit an anti-inflammatory action and a Z or cancer preventive effect.
- anti-inflammatory agents or cancer preventive agents of the present invention which contain cosmetic ingredients, for treatment against one or more of skin aging, cell injury and sunburn power
- the product has an effect that treatment for a wide variety of inflammations can be performed by the same treatment method as that for general cosmetics.
- anti-inflammatory agents or cancer preventive agents those having the form of creams, tablets, capsules, oil preparations, water-soluble drugs (water-soluble drugs) or emulsions If treatment of diseases and the like can be performed more easily, the effects are achieved.
- anti-inflammatory agents or cancer preventive agents of the present invention those further containing food ingredients exhibit anti-inflammatory action and Z or cancer preventive effects when taken in the same manner as ordinary foods.
- FIG. 1 is a diagram showing the structure of canolol.
- FIG. 2 is a diagram showing the anti-inflammatory action of the anti-inflammatory agent of the present invention.
- FIG. 3A is a diagram showing pathological findings after immunostaining with COX-2.
- FIG. 3B is a diagram showing pathological findings after immunostaining with iNOS.
- FIG. 4 is a graph showing suppression of NO production from macrophages by the anti-inflammatory agent of the present invention.
- FIG. 5 is a graph showing the effect of the anti-inflammatory agent of the present invention on macrophage survival.
- FIG. 6 is a graph showing the effect of the cancer preventive agent of the present invention on gene damage caused by ONOO—.
- FIG. 7A shows a strain after ONOO_ is continuously injected under stirring.
- FIG. 7B is a diagram showing mutant strains.
- FIG. 7C is a graph showing the inhibitory effect of the cancer preventive agent of the present invention on the expression of mutant strains.
- composition and form of the anti-inflammatory agent and cancer preventive agent of the present invention and pharmaceuticals, cosmetics and foods containing them are not limited as long as they contain cananolol or its PD.
- canolol or its PD can be obtained by extraction of rapeseed according to the method described in W02003 / 030888, for example.
- canolol can be synthesized from sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid) or phenol by a method known per se.
- various dosage forms containing 0.1 to 5% are preferred, and more preferred are various dosage forms containing 0.1 to 3%.
- the anti-inflammatory agent of the present invention may contain camphor, sucralfate, methyl salicylate, teprenone, and the like as components of the supplement. Those containing teprenone are preferred.
- the anti-inflammatory agent of the present invention has an anti-inflammatory action against various inflammations.
- inflammation include gastric / duodenal inflammation, gastric / duodenal ulcer, gastritis, bronchitis, rheumatism, hepatitis, colitis, conjunctivitis, pneumonia, splenitis, stomatitis, pharyngitis and burns 1 or 2 More than species. Since the anti-inflammatory agent of the present invention exhibits an excellent action particularly against gastroduodenal inflammation, the anti-inflammatory agent of the present invention is preferably used for these inflammations.
- the cancer preventive agent of the present invention should contain sucralfate teprenone as an additional component.
- the cancer preventive agent of the present invention has a preventive action against various cancers.
- cancer include one or more of stomach cancer, colon cancer, liver cancer, gallbladder cancer, bile duct cancer, esophageal cancer, and lung cancer.
- the cancer preventive agent of the present invention exhibits an excellent action particularly for preventing the occurrence of gastric cancer
- the cancer preventive agent of the present invention is preferably used for these cancers.
- the anti-inflammatory agent or cancer preventive agent of the present invention may contain water, an organic solvent, an emulsifier, an oil and the like as a general auxiliary component.
- Other components are appropriately modified depending on the application.
- the medical composition containing the anti-inflammatory agent or cancer preventive agent of the present invention is an anti-inflammatory agent or cancer preventive agent comprising canolol or PD thereof as an active ingredient, and is a human medicine or veterinary medicine.
- Can be used effectively as Pharmaceutical excipients suitable for formulating the medicament of the present invention are suitable for enteral (eg oral), parenteral or topical administration, and organic or inorganic substances which do not react with the compound, eg water, vegetable oil , Benzyl alcohol, alkylene glycol, polyethylene glycol, glyceroretriacetate, carbohydrates such as gelatin, lactose or starch, magnesium stearate, talc or petrolatum.
- Suitable for oral administration are in particular tablets, pills, coated tablets, capsules, powders, granules, syrups, juices, solutions, suspensions or drops, suitable for rectal administration are suppositories, Suitable for parenteral administration are solutions, preferably oil-based or aqueous solutions, also suspensions, emulsions or implants, and suitable for topical application are ointments, creams or powders, or patches It is done transcutaneously.
- canolol exhibits activity in oral administration, and the viewpoint power of administration is oral. Since powerful oral administration can be performed very easily by the subject itself, it is also preferable from the viewpoint of improving compliance, such as saving labor.
- a purified lyophilized product that may be freeze-dried, for example, may be used for the production of an injection preparation.
- the indicated formulations may be sterilized and Z or auxiliary agents such as lubricants, preservatives, stabilizers, and Z or wetting agents, emulsifiers
- Suitable formulations for administration in the form of an aerosol or spray are, for example, solutions, suspensions or emulsions of the active ingredient of the formula I in a pharmaceutically acceptable solvent.
- the medicament of the present invention is preferably administered at a dose of 1 to 5 OOmg, particularly preferably 5 to: LOOmg as an amount of the active ingredient per dose unit.
- the daily dose is about 0.01 to: LOOmg per kg body weight, preferably about 0.1 to 80 mg per kg body weight, particularly preferably about 1 to 70 mg per kg body weight.
- the specific dose to each patient will depend on a wide range of factors such as the effectiveness of the specific compound used, age, weight, general health status, gender, diet, time and method of administration. Depending on the severity of the particular disease to which the excretion rate, pharmaceutical combination and treatment are applied. Oral administration is preferred.
- the present invention further relates to the manufacture of the medicament of the present invention, in particular for use by non-chemical methods.
- the active ingredients of these drugs, canolol and its PD, together with at least one solid, liquid and Z or semi-liquid excipients or auxiliaries and, if desired, one or more than one Suitable in combination with further active ingredients Can be converted into various dosage forms.
- inflammation include one or more of skin aging, cell damage and sunburn. Since the cosmetic product of the present invention exhibits excellent action against inflammation caused by sunburn, ultraviolet rays and heat rays, the cosmetic product of the present invention is preferably used for these inflammations.
- “(Hereinafter referred to as“ PD ”) means a drug that is inactive as it is, but only shows an activity in vivo when it undergoes a chemical change by a drug-metabolizing enzyme.
- the PD of canolol is not limited to that used in the present invention, but examples thereof include prodrugs represented by the following formula:
- R represents a carboxyl residue having 1 to 24 carbon atoms.
- R is preferably a fatty acid residue having 1 to 24 carbon atoms, an amino acid residue, a peptide spacer, a sugar residue, or an organic acid residue, and more preferably CH 2 CO—, CH 2 CO—, NH 2 CH 3 CO—
- R ′ represents an amino acid side chain residue
- Preferable examples of the peptide spacer include Gly-Phe-Leu-Gly.
- sugar residues include sugar residues of sugars such as glucuronic acid, uronic acid, ascorbic acid, sialic acid, hyaluric acid and hyaluronic acid.
- organic acid residue include organic acid residues of organic acids such as malic acid, citrate, oxalic acid, malonic acid, and succinic acid.
- Esters, amide bonds, and spacer peptides with these acyl groups It is hydrolyzed by esterase, amidase, and cathebsin 'peptidase to release the original drug, canolol.
- canolol can be more efficiently delivered to its site of operation or a lipophilic dosage form can be more easily produced.
- carotene such as beta-carotene, tocopherol, vitamin C and its derivatives, melanin, chlorophyll, ligne, phthalic acid, kojic acid, BHT (butyl hydroxy) Toluene
- beta-carotene and Z or tocopherol.
- Examples of powerful cosmetic ingredients include excipients, fragrances, coloring materials, and other active ingredients.
- oils and fats such as olive oil, beeswax, lanolin, candelilla wax, squalane, paraffin, stearic acid, cetanol, octyldodecyl myristate, tri (capryl'force purinic acid) glycerin;
- Water-soluble polymer compounds such as sodium alginate, dextrin, carboxymethyl cellulose sodium, canoleboxinvinole polymer, polyvinyl alcohol; polyhydric alcohols such as propylene glycol and polyethylene glycol; sugars such as glucose, sorbitol, maltitol;
- Surfactants such as sorbitan monostearate, polyoxyethylene glyceryl monostearate, polyoxyethylene nouryl ether, and the like can be used alone or 2 Used as a mixture of at least.
- perfumes are recommended as embodiments herein to enhance their palatability.
- Any natural or synthetic flavor can be used in the present invention.
- one or more plants and Z or fruit flavors may be used in the present invention.
- the strong flavor can be synthetic or natural! /.
- the combination is preferred.
- the perfume can also include a mixture of various flavors. If desired, the flavor in the perfume can be formed into emulsified droplets, which are then dispersed in the beverage composition or concentrate. Typically, the perfume is as a concentrate or extract or combined. It can be easily obtained in the form of flavourantly produced flavor esters, alcohols, aldehydes, terpenes, sesquiterpenes and the like.
- coloring material examples include tar dyes such as red No. 2 and blue No. 1 and inorganic dyes such as talc, my strength and titanium oxide.
- the other active ingredients are appropriately selected according to the use of the cosmetic product of the present invention.
- effective active ingredients include vitamins such as vitamin E, vitamin C and vitamin D; Animal and plant extract ingredients such as extract, aloe extract, bracentr; antioxidants such as dibutylhydroxytoluene; antiplasmin agents such as epsilon aminocaproic acid and tranexamic acid; paramethoxycinnamic acid ethylhexyl ester, oxybenzone, etc.
- Examples include ultraviolet absorbers.
- the amount of each of these cosmetic ingredients varies depending on the intended cosmetic, and is preferably adjusted appropriately according to the intended use.
- Examples of the cosmetic form of the present invention include creams, tablets, capsules, oil preparations, water-soluble drugs (water-solubilized products), and emulsions.
- composition containing various food ingredients that is, the food, weighted to the anti-inflammatory agent or cancer preventive agent of the present invention, that is, the food has anticancer action and Z or anti-inflammatory action by containing canolol.
- the food of the present invention contains at least one food ingredient together with canolol.
- Examples of food ingredients include proteins, carbohydrates, fats, vitamins and minerals.
- Non-limiting examples of vitamins and minerals include niacin, thiamine, folic acid, pantothenic acid, vivid chin, vitamin A, vitamin C, vitamin B, vitamin B, vitamin B, vitamin
- vitamin D vitamin E
- vitamin K iron
- zinc copper
- copper phosphorus
- iodine chromium
- molybdenum molybdenum
- vitamins or minerals are used, the vitamins or minerals are niacin, thiamine, folic acid, iodine, vitamin ⁇ , vitamins, vitamin ⁇ , vitamin ⁇ , vitamin D, vitamin E, iron, zinc and calcium.
- the vitamins or minerals are niacin, thiamine, folic acid, iodine, vitamin ⁇ , vitamins, vitamin ⁇ , vitamin ⁇ , vitamin D, vitamin E, iron, zinc and calcium.
- vitamin B selected from vitamin E, pantothenic acid, niacin, and piotin. Also
- the composition comprises vitamin C and vitamin B, vitamin B, vitamin E, pante Tonic acid, niacin, and piotin power Contains one or more other vitamins selected.
- the food products of the present invention may contain an effective amount of one or more sweeteners, including carbohydrate sweeteners and natural and Z or artificial non-calorie Z low calorie sweeteners. And usually contains.
- the amount of sweetener used in the beverages of the present invention typically depends on the particular sweetener used and the desired sweetness intensity. For non-calorie Z low-calorie sweeteners, this amount varies with the sweetness intensity of the individual sweetener.
- the food products of the present invention can be sweetened with any carbohydrate sweetener, preferably monosaccharides, and Z or -sugars.
- Sweetened beverages typically contain from about 0.1% to about 20% sweetener, most preferably from about 6% to about 14%.
- These sugars can be contained in solid or liquid form, but are typically incorporated into beverages as concentrated syrups, preferably syrups, most preferably high fructose corn syrups.
- these sugar sweeteners can be provided to some extent by, for example, fruit juice components and other components of the beverage such as Z or flavor.
- Example (1) Action concerning gastritis suppressing action.
- MNU carcinogen N-methylnitrosourea
- H. pylori was first infected with 1 X 10 8 CFU and MNIX 10 ppm was administered for 1 week
- a normal diet-free group with the same feed composition as that of the same feed composition was prepared and reared for 52 weeks (X. Cao et al, Jpn. J. Cancer Res., 93, 12 93-1298 (2002), N Shimizu, et al, Cancer Res., 60, 1512—1514 (2000)).
- the gerbils were tested in 10 groups.
- 8 OHdG is one of the markers of inflammatory disorders that occur as a result of the reaction of reactive oxygen with DNA by generating reactive oxygen derived from inflammatory cells in vivo.
- the amount of 8 OHdG produced was examined by the usual enzyme antibody immunization method using anti-8 OHdG antibody on the stomach excised specimen of each group after 12 weeks.
- Table 1 although it showed an inhibitory action against the production of canolol force OHdG, no antibacterial action was observed. Therefore, since it has an inhibitory action on the production of Canonolka 8-OHdG, it was revealed that it has an anti-inflammatory action, that is, an action to suppress gastritis.
- Table 1 Table 1. 8-O H G production and Helicobacter pylori count (C F U) in gastric tissues infected with Helicobacter pylori in each group
- Example 2 A sample after 12 weeks of administration in Example (1) was prepared, and after staining with normal hematoxylin eosin, a stomach sample was prepared and evaluated under a microscope. The results are shown in Table 2.
- Example (4) Induction of cyclooxygenase 2 (COX-2) and determination of enzyme activity of inducible NO synthase (iNOS) in gastric lesions infected with Helicobacter pylori
- COX-2 and iNOS induced during inflammation are typical enzymes for developing an inflammatory response. That is, COX-2 is a prostanoid inflammatory mediator such as prostaglandin E, and iNOS is nitric oxide (NO).
- the inflammatory mediator and NO are both substances that cause inflammation. Furthermore, both active oxygen 0- and NO generated in the field of inflammation react immediately,
- FIG. 3A shows COX-2 and FIG. 3B shows pathological findings after immunostaining of iNOS.
- Table 3 shows the quantification of both enzymes from immunostaining using each of these antibodies.
- Inflammation control group (Cano 2.2 ⁇ 0.2 1.7 ⁇ 0.2 1.0 ⁇ 0.2 0.8 ⁇ 0.2 No roll)
- the results are shown in FIG.
- the medium used was RPMI-1640 supplemented with 10% inactivated rabbit fetal serum.
- the group treated with LPS alone or with LPS and IFN-y alone and without a canola roll was used as a control.
- the vertical axis represents the total amount of nitrate and sulfite ions.
- canolol has a cytotoxic effect on macrophages at 800 mg and above, and is suitable for use as a drug having no cytotoxicity at 100 mg and below in its effective concentration range (Fig. 5).
- Peroxinitrite is excessively produced as part of the inflammatory reaction in the inflamed area, and its toxicity to living cells is one of the etiology. It was considered that canolol has a protective effect against the toxicity of ⁇ - to cultured cells.
- Dojindo Chemical Co., Ltd. a reagent for generating peroxynitrite (ONOCT), prepared by preparing 96-well microplates with human airway (HBE140) and human embryonic kidney epithelial cells ⁇ 293 each (1 X 10 5 cells / well) Using SIN-1 [(3— (4 morpholynyl) sydononimine HC1)] (10 0 ⁇ ) in the presence of canolalol (5, 12.5, 25, 50, 100 ⁇ ) or without a control group Then, the cell viability according to the above was quantified using an acupuncture method. The result is shown in FIG. At this time, the approximate half-life of SIN-1 in the culture medium was 6 hours.
- anti-inflammatory agents of the present invention have found virulence neutralizing effect against significant ONOO _ renal epithelium cells 293 in 12.5 ⁇ 50 i u M.
- Example (7) Suppression of gastric cancer in gerbils administered with Helicobacter pylori infection and carcinogen methylnitrosourea (MNU)
- gerbils are bred for 20 weeks or more, opened under anesthesia around 57 weeks, the stomach is removed and fixed, and the paraffin specimen is prepared by a conventional method.
- the slices were stained with HE (hematoxylin'eosin) and examined under a microscope.
- Table 4 shows the results of counting the number of each gerbil in the case determined to be carcinoma at that time.
- the carcinogenic rate was significantly suppressed (64%), 41% in the control (no canola) group, 15% in the canola group. This shows that canolol suppresses the gene damage caused by ONOO-, which is observed in the mutagenicity-suppressing effect of salmonella peroxynitrite ONOO- shown in Fig. 6.
- BHT a Sand mice were given methylnitrosourea (MNU) after infection with Helicobacter pylori (Hp) in 10 ppm drinking water, and one week later, they were reared by switching to a test diet containing 0.1% canolalol in the diet.
- MNU methylnitrosourea
- Hp Helicobacter pylori
- canolol can be a cancer preventive agent. From these series of experiments, the protective power of canolol against ONOO- cytotoxicity became clear. Therefore, the composition containing canolol can be used as an anti-inflammatory agent or a cancer preventive agent.
- canolol can also be used as an ingredient in cosmetics and foods that can be used as an anti-inflammatory agent and cancer preventive agent by being administered to a living body.
- canolalol typically prescriptions of pharmaceuticals, cosmetics and foods containing canolalol are shown.
- Example (9) Cream Canolol-containing anti-inflammatory cream (ointment)
- antioxidants e.g., various vegetable and animal
- lanolin petrolatum, coconut oil, palm oil, camellia oil, other hydrogenated vegetable oils and fats, glycerin, etc. or mixtures thereof
- BHT (2, 6-di-10-butyl-4-methylphenol: t-butylated hydroxytoluene) or ⁇ -tocopherol or a derivative such as vitamin C is added 0.001 to 0.1%, preferably 0.01%.
- Canolol-containing emulsions and solution formulations 10 ml of an aqueous solution containing a trace amount of an antioxidant (for example, palmitole arcovic acid derivative or PD, BHT, etc.), and 0.1 to 10 ml of ethanolol or propanol, or 10 ml of isopropanol.
- canolol is contained in an alcohol or its aqueous solution in an amount of 0.1 to 50%.
- Canolaol is made from soybean oil, sesame oil, rapeseed oil, olive oil, medium chain fatty acids, linoleic acid, It can be dissolved in oil of baki oil, poppy oil, etc. so that it becomes 0.1 to 50%, and it can be made into oil. Fill itself with soft gel capsules, etc., 0.1 to 0.5g of canolol. The capsule can be taken orally as an anti-inflammatory agent 1 to 10 tablets per day.
- canolol Take as a tablet containing canolol.
- base materials for tablets lactose, maltose, various starches, cellulose, chitin, chitosan, hemicellose, polybutyl alcohol, polyethylene glycol, calcium phosphate, etc.
- a solution in which 1 to 50% of Canonol is dissolved in ethanol containing 0.01 to 0.1% of a general antioxidant, or Canonol itself is added to the tablet substrate, stirred until uniform, and then dried under reduced pressure to remove ethanol. Except for tableting. Obtain 1 to 500 mg per tablet.
- 3 to 5 tablets can be taken after meals 3 times a day.
- canolol Dissolve 100 ml of canolol in 1 ml of alcohol (such as ethanol), and 50-100 times its volume of distilled water, physiological food PD water, 5% glucose solution, 8% sodium bicarbonate water, manitol solution, lactose solution, Alternatively, the above-mentioned canolol can be added to a drip medicinal solution such as intralipid, a vitamin mixture, and an amino acid mixture, a supplement solution, or the like to make an injection.
- alcohol such as ethanol
- canolol is made into micelles or cyclodextrin conjugates by using various micellar agents, or sugar esters such as lecithin, sphingomyelin, and -uckol are added to make emulsion suspensions, or into high-calorie supplements such as intralipids. Add or water-soluble injection.
- concentration of canolalol per lml is 1 to 300 mg, preferably 50 to 80 mg / ml.
- Example (15) Make a cosmetic by adding excipients, fragrances, coloring materials and other active ingredients to the Canonol solution and formulating it into an appropriate dosage form.
- a variety of foods, drinking water, drinks, biscuits and BHT or vitamin C are added to the food to contain 0.01% to 2.0% of the above-mentioned food.
- Carcinogenesis can be suppressed by ingesting the food. That is, the food is used as a chemopreventive agent for cancer.
- the anti-inflammatory agent and cancer preventive agent of the present invention as well as pharmaceuticals, cosmetics and foods containing them, have sufficient anti-inflammatory activity and anti-wrinkle or cancer preventive activity, and are easy to produce, cost of production, Biological activity, safety, administration * Even in the case of ingestion, it has an exceptional effect over conventional ones. Therefore, the present invention greatly contributes to the development of the pharmaceutical industry, cosmetic industry, food industry and related industries.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06730565A EP2014283A4 (en) | 2006-03-30 | 2006-03-30 | ANTI-INFLAMMATORY AGENT AND CANCER PREVENTION AGENT COMPRISING CANOLOL OR A PRODRUCE THEREOF AND PHARMACEUTICAL, COSMETIC AND FOOD PRODUCT COMPRISING THE SAME |
CA002659767A CA2659767A1 (en) | 2006-03-30 | 2006-03-30 | Anti-inflammatory agent and cancer-preventive agent comprising canolol or prodrug thereof and pharmaceutical, cosmetic and food comprising the same |
JP2008509584A JP5222131B2 (ja) | 2006-03-30 | 2006-03-30 | キャノロールまたはそのプロドラッグ(pd)を含む抗炎症剤および癌予防剤ならびにこれらを含む医薬、化粧品および食品 |
US12/294,972 US20090163600A1 (en) | 2006-03-30 | 2006-03-30 | Anti-Inflammatory Agent and Cancer-Preventive Agent Comprising Canolol or Prodrug Thereof and Pharmaceutical, Cosmetic and Food Comprising the Same |
PCT/JP2006/306617 WO2007116432A1 (ja) | 2006-03-30 | 2006-03-30 | キャノロールまたはそのプロドラッグ(pd)を含む抗炎症剤および癌予防剤ならびにこれらを含む医薬、化粧品および食品 |
TW095115028A TW200735857A (en) | 2006-03-30 | 2006-04-27 | Anti inflammation agent and cancer preventing agent comprising canorol or a prodrug (PD) thereof, and medicaments, cosmetics and foods containing the same |
US13/354,507 US8865775B2 (en) | 2006-03-30 | 2012-01-20 | Anti-inflammatory agent and cancer-preventive agent comprising canolol or prodrug thereof and pharmaceutical, cosmetic and food comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/306617 WO2007116432A1 (ja) | 2006-03-30 | 2006-03-30 | キャノロールまたはそのプロドラッグ(pd)を含む抗炎症剤および癌予防剤ならびにこれらを含む医薬、化粧品および食品 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/354,507 Continuation US8865775B2 (en) | 2006-03-30 | 2012-01-20 | Anti-inflammatory agent and cancer-preventive agent comprising canolol or prodrug thereof and pharmaceutical, cosmetic and food comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007116432A1 true WO2007116432A1 (ja) | 2007-10-18 |
Family
ID=38580741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/306617 WO2007116432A1 (ja) | 2006-03-30 | 2006-03-30 | キャノロールまたはそのプロドラッグ(pd)を含む抗炎症剤および癌予防剤ならびにこれらを含む医薬、化粧品および食品 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20090163600A1 (ja) |
EP (1) | EP2014283A4 (ja) |
JP (1) | JP5222131B2 (ja) |
CA (1) | CA2659767A1 (ja) |
TW (1) | TW200735857A (ja) |
WO (1) | WO2007116432A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012110273A (ja) * | 2010-11-25 | 2012-06-14 | Kagoshima Univ | 焙煎全脂ナタネ種子成分を含む飲食品、医薬品、および飼料 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10959968B2 (en) | 2016-01-13 | 2021-03-30 | Board Of Supervisors Of Louisiana State University | Methods for treating c-Met-dependent cancers |
CN110615731B (zh) * | 2019-09-16 | 2022-10-14 | 中国农业科学院油料作物研究所 | 一种制备2,6-二甲氧基-4-乙烯基苯酚的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003030888A1 (fr) | 2001-10-09 | 2003-04-17 | The Japanese Research And Development Association For New Functional Foods | Anti-radicaux et compositions lipidiques, aliments, boissons, medicaments ou aliments pour animaux contenant ces anti-radicaux |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
-
2006
- 2006-03-30 WO PCT/JP2006/306617 patent/WO2007116432A1/ja active Application Filing
- 2006-03-30 EP EP06730565A patent/EP2014283A4/en not_active Withdrawn
- 2006-03-30 US US12/294,972 patent/US20090163600A1/en not_active Abandoned
- 2006-03-30 JP JP2008509584A patent/JP5222131B2/ja not_active Expired - Fee Related
- 2006-03-30 CA CA002659767A patent/CA2659767A1/en not_active Abandoned
- 2006-04-27 TW TW095115028A patent/TW200735857A/zh unknown
-
2012
- 2012-01-20 US US13/354,507 patent/US8865775B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003030888A1 (fr) | 2001-10-09 | 2003-04-17 | The Japanese Research And Development Association For New Functional Foods | Anti-radicaux et compositions lipidiques, aliments, boissons, medicaments ou aliments pour animaux contenant ces anti-radicaux |
Non-Patent Citations (11)
Title |
---|
A. KANAZAWA ET AL., EUR. J. LIPID SCIENCE TECH., vol. 104, 2002, pages 439 - 447 |
D. WAKAMATSU ET AL., BIOSCI., BIOTECH., BIOCHEM., vol. 69, 2005, pages 1568 - 1574 |
H. KUWAHARA ET AL., J. AGRIC. FOOD CHEM., vol. 52, 2004, pages 4380 - 4387 |
J. K. KUNDU; Y J. SURH, MUTATION RES., vol. 591, 2005, pages 123 - 146 |
JOLAD S.D. ET AL.: "Commercially processed dry ginger (Zingiber officinale): Composition and effects on LPS-stimulated PEG2 production", PHYTOCHEMISTRY (ELSEVIER), vol. 66, no. 13, 2005, pages 1614 - 1635, XP004971548 * |
N. SHIMIZU ET AL., CANCER RES., vol. 60, 2000, pages 1512 - 1514 |
See also references of EP2014283A4 * |
STUEHR DJ ET AL., J. EXP. MED., vol. 169, 1989, pages 1543 - 55 |
T. SAWA ET AL., CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION, vol. 7, 1998, pages 1007 - 1012 |
VUORELA S. ET AL.: "Preclinical evaluation of rapeseed, raspberry, and pine bark phenolics for health related effects", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 53, no. 15, 2005, pages 5922 - 5931, XP003018512 * |
X. CAO, JPN. J. CANCER RES., vol. 93, 2002, pages 1293 - 1298 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012110273A (ja) * | 2010-11-25 | 2012-06-14 | Kagoshima Univ | 焙煎全脂ナタネ種子成分を含む飲食品、医薬品、および飼料 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007116432A1 (ja) | 2009-08-20 |
US8865775B2 (en) | 2014-10-21 |
EP2014283A1 (en) | 2009-01-14 |
TW200735857A (en) | 2007-10-01 |
JP5222131B2 (ja) | 2013-06-26 |
US20090163600A1 (en) | 2009-06-25 |
EP2014283A4 (en) | 2010-04-21 |
US20120122995A1 (en) | 2012-05-17 |
CA2659767A1 (en) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4205943B2 (ja) | 天然および合成hcaのバイオアベイラブルな組成物 | |
WO2008062861A1 (fr) | Poudre d'extrait de plante contenant de l'indigo, procédé de fabrication de celle-ci et utilisation de celle-ci | |
KR20150021465A (ko) | 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
JP6218870B2 (ja) | ジンセノサイドf2を含む非アルコール性肝疾患又はインスリン抵抗性の予防若しくは治療用組成物 | |
JP4839436B2 (ja) | 消化管粘膜保護剤、カベオリン遺伝子発現促進剤及び抗ストレス剤 | |
EP1734946B1 (en) | Punicic acid for use to enhance immune response and treating inflammatory bowel disease | |
JPWO2006135084A1 (ja) | 脂肪性肝炎または脂肪肝の予防または治療薬 | |
JP2011195531A (ja) | タンパク質糖化抑制剤 | |
JP5222131B2 (ja) | キャノロールまたはそのプロドラッグ(pd)を含む抗炎症剤および癌予防剤ならびにこれらを含む医薬、化粧品および食品 | |
JP2001064172A (ja) | Apc遺伝子の変異に起因する疾患の予防・治療剤 | |
JP2011195530A (ja) | タンパク質糖化抑制剤 | |
KR20160068315A (ko) | 홍화황 추출물을 포함하는 미백용 조성물 | |
KR20190131817A (ko) | 난용성 물질인 커큐민을 포함하는 진세노사이드 복합체 | |
KR100654903B1 (ko) | 인진, 갈근 및 차조기를 포함하는 항염 또는 연골 재생용 조성물 | |
KR101071852B1 (ko) | 도코사헥사에노일 리소포스파티딜콜린을 유효성분으로 함유하는 항염증 조성물 | |
KR102032830B1 (ko) | 쌀겨 추출물을 함유하는 피부 개선용 건강기능식품 | |
JP4413272B1 (ja) | ヒアルロン酸産生促進剤 | |
KR100485936B1 (ko) | 진세노사이드 Rh2 및 Rg3 항암 조성물 | |
KR20160068316A (ko) | 황벽 추출물을 포함하는 미백용 조성물 | |
KR20190142672A (ko) | 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물 | |
KR20140104090A (ko) | 커큐민을 유효성분으로 포함하는 지방간 질환의 치료 또는 예방용 조성물 | |
JP6928337B2 (ja) | No産生抑制剤 | |
JP2002220333A (ja) | 経口美白剤 | |
KR20240040441A (ko) | 검은지느러미 빙어 추출물 또는 에메랄드 암치 추출물을 유효성분으로 포함하는 항염증용 조성물 | |
JP2002121132A (ja) | 発がん抑制剤および発がん抑制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06730565 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008509584 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2659767 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006730565 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12294972 Country of ref document: US |